Amgen Inc (OQ:AMGN)
Business Focus: Pharmaceuticals
| Sector: Healthcare | Industry: Pharmaceuticals |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | One Amgen Center Drive THOUSAND OAKS CA 91320 |
| Tel: | N/A |
| Website: | https://www.amgen.com |
| IR: | See website |
| Key People | ||
| Robert A. Bradway Chairman of the Board, President, Chief Executive Officer | Rachna Khosla Senior Vice President - Business Development | Peter H. Griffith Chief Financial Officer, Executive Vice President |
| David M. Reese Executive Vice President, Chief Technology Officer | James Bradner Executive Vice President, Research and Development, and Chief Scientific Officer | Jonathan P. Graham Executive Vice President, General Counsel, Secretary |
| Lori A. Johnston Executive Vice President - Human Resources | Murdo Gordon Executive Vice President - Global Commercial Operations | Esteban Santos Executive Vice President - Operations | Nancy A. Grygiel Senior Vice President, Chief Compliance Officer |
| Business Overview |
| Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company's marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others. |
| Financial Overview |
| For the three months ended 31 March 2024, Amgen Inc revenues increased 22% to $7.45B. Net loss totaled $113M vs. income of $2.84B. Revenues reflect XGEVA segment increase of 41% to $561M, Repatha segment increase of 33% to $517M. Net loss reflects Other income, net - Balancing value decrease from $1.95B (income) to $368M (expense), Selling, general and administrative increase of 44% to $1.81B (expense). |
| Employees: | 26,700 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $220,687M as of Mar 31, 2024 |
| Annual revenue (TTM): | $29,532M as of Mar 31, 2024 |
| EBITDA (TTM): | $11,625M as of Mar 31, 2024 |
| Net annual income (TTM): | $3,763M as of Mar 31, 2024 |
| Free cash flow (TTM): | $2,471M as of Mar 31, 2024 |
| Net Debt Last Fiscal Year: | $54,312M as of Mar 31, 2024 |
| Shares outstanding: | 536,434,692 as of Apr 29, 2024 |
| Index Membership: | S&P 500, Dow Industry |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.